Investigational Drug Information for Aldoxorubicin
✉ Email this page to a colleague
What is the drug development status for Aldoxorubicin?
Aldoxorubicin is an investigational drug.
There have been 20 clinical trials for Aldoxorubicin.
The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2014.
The most common disease conditions in clinical trials are Neoplasms, Sarcoma, and Pancreatic Neoplasms. The leading clinical trial sponsors are ImmunityBio, Inc., CytRx, and NantKwest, Inc.
There are twenty-three US patents protecting this investigational drug and three hundred and twenty-six international patents.
Summary for Aldoxorubicin
| US Patents | 23 |
| International Patents | 326 |
| US Patent Applications | 118 |
| WIPO Patent Applications | 107 |
| Japanese Patent Applications | 43 |
| Clinical Trial Progress | Phase 3 (2014-01-01) |
| Vendors | 27 |
Recent Clinical Trials for Aldoxorubicin
| Title | Sponsor | Phase |
|---|---|---|
| Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for First and Second Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer | ImmunityBio, Inc. | Phase 2 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | ImmunityBio, Inc. | Phase 2 |
| QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine | NantKwest, Inc. | Phase 2 |
Clinical Trial Summary for Aldoxorubicin
Top disease conditions for Aldoxorubicin
Top clinical trial sponsors for Aldoxorubicin
US Patents for Aldoxorubicin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Aldoxorubicin | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Crystalline forms of C.sub.21H.sub.22Cl.sub.2N.sub.4O.sub.2 | Biomed Valley Discoveries, Inc. (Kansas City, MO) Vertex Pharmaceuticals Incorporated (Boston, MA) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Anthracycline formulations | CytRx Corporation (Los Angeles, CA) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Enzyme-responsive peptide nanofiber compositions and uses thereof | CORNELL UNIVERSITY (Ithaca, NY) | See Plans and Pricing |
| Aldoxorubicin | See Plans and Pricing | Combinatorial methods to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (Melbourne, AU) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Aldoxorubicin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Aldoxorubicin | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | Hong Kong | HK1249728 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | Japan | JP2019520866 | 2036-05-05 | See Plans and Pricing |
| Aldoxorubicin | Japan | JP6559912 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
